Shui He

2.4k total citations · 2 hit papers
38 papers, 1.7k citations indexed

About

Shui He is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Shui He has authored 38 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Shui He's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), CAR-T cell therapy research (9 papers) and Lymphoma Diagnosis and Treatment (8 papers). Shui He is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), CAR-T cell therapy research (9 papers) and Lymphoma Diagnosis and Treatment (8 papers). Shui He collaborates with scholars based in United States, Italy and United Kingdom. Shui He's co-authors include Melissa Saul, Kyle J. Gunnerson, John A. Kellum, Alessandro M. Vannucchi, Srđan Verstovšek, Francesco Passamonti, Jean‐Jacques Kiladjian, Mark M. Jones, Jingjin Li and Pierre Zachée and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Shui He

37 papers receiving 1.6k citations

Hit Papers

Ruxolitinib versus Standard Therapy for the Treatment of ... 2015 2026 2018 2022 2015 2021 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
    2015 594 citations Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →
  2. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
    2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shui He United States 13 749 560 476 470 372 38 1.7k
Bruno Royer France 27 741 1.0× 623 1.1× 1.1k 2.3× 1.3k 2.9× 414 1.1× 84 2.5k
Piera Viero Italy 24 737 1.0× 675 1.2× 1.2k 2.6× 336 0.7× 438 1.2× 81 2.3k
P. W. Wijermans Netherlands 18 304 0.4× 438 0.8× 792 1.7× 323 0.7× 330 0.9× 49 1.6k
Eirini Katodritou Greece 24 555 0.7× 1.4k 2.5× 1.5k 3.2× 984 2.1× 230 0.6× 108 2.5k
Megan O. Nakashima United States 18 371 0.5× 174 0.3× 371 0.8× 285 0.6× 391 1.1× 55 1.5k
Paolo G. Gobbi Italy 29 686 0.9× 905 1.6× 435 0.9× 313 0.7× 1.6k 4.2× 86 2.6k
Achille Ambrosetti Italy 24 1.3k 1.8× 713 1.3× 798 1.7× 383 0.8× 1.5k 4.1× 67 2.8k
David Lawrence United States 29 764 1.0× 614 1.1× 1.5k 3.3× 1.1k 2.3× 500 1.3× 73 3.3k
Lars Møller Pedersen Denmark 28 972 1.3× 1.4k 2.5× 189 0.4× 405 0.9× 2.1k 5.7× 103 3.4k
Canellos Gp United States 20 412 0.6× 361 0.6× 516 1.1× 116 0.2× 477 1.3× 49 1.3k

Countries citing papers authored by Shui He

Since Specialization
Citations

This map shows the geographic impact of Shui He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shui He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shui He more than expected).

Fields of papers citing papers by Shui He

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shui He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shui He. The network helps show where Shui He may publish in the future.

Co-authorship network of co-authors of Shui He

This figure shows the co-authorship network connecting the top 25 collaborators of Shui He. A scholar is included among the top collaborators of Shui He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shui He. Shui He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Lihua, et al.. (2025). Study on the regulation of gastric cancer cell apoptosis by LACTB through mitochondrial autophagy pathway. Scientific Reports. 15(1). 23273–23273.
2.
Spira, Alexander I., Michael S. Gordon, Jason T. Henry, et al.. (2023). 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors. SHILAP Revista de lepidopterología. A852–A852. 1 indexed citations
3.
Hu, Lihua, et al.. (2023). A potential therapeutic approach for gastric cancer: inhibition of LACTB transcript 1. Aging. 15(24). 15213–15227. 2 indexed citations
4.
Wilks, Sharon, Benedito A. Carneiro, Gregory M. Coté, et al.. (2023). 762 A first-in-human phase 1 clinical study evaluating safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the EDB+FN targeting ADC PYX-201 in participants with advanced solid tumors. SHILAP Revista de lepidopterología. A857–A857. 1 indexed citations
5.
6.
Hamadani, Mehdi, Graham P. Collins, Paolo F. Caimi, et al.. (2021). Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. The Lancet Haematology. 8(6). e433–e445. 63 indexed citations
7.
Caimi, Paolo F., Weiyun Z. Ai, Juan Pablo Alderuccio, et al.. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 22(6). 790–800. 264 indexed citations breakdown →
8.
Kahl, Brad S., Mehdi Hamadani, John Radford, et al.. (2019). A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 25(23). 6986–6994. 77 indexed citations
9.
10.
Hamadani, Mehdi, Graham P. Collins, Felipe Samaniego, et al.. (2018). Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma. Blood. 132(Supplement 1). 928–928. 35 indexed citations
11.
Goldberg, Aaron D., Martin S. Tallman, Melhem Solh, et al.. (2017). Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia. Blood. 130. 2662–2662. 8 indexed citations
12.
13.
Vannucchi, Alessandro M., Jean‐Jacques Kiladjian, Martin Grießhammer, et al.. (2015). Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine. 372(5). 426–435. 594 indexed citations breakdown →
14.
Mesa, Ruben A., Srđan Verstovšek, Jean‐Jacques Kiladjian, et al.. (2014). Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results. Blood. 124(21). 709–709. 1 indexed citations
15.
Verstovšek, Srđan, Francesco Passamonti, Alessandro Rambaldi, et al.. (2013). A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 120(4). 513–520. 131 indexed citations
16.
Vannucchi, Alessandro M., Jean‐Jacques Kiladjian, Martin Grießhammer, et al.. (2013). Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea. Blood. 122(21). 4071–4071. 7 indexed citations
17.
Gunnerson, Kyle J., Melissa Saul, Shui He, & John A. Kellum. (2006). Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. Critical Care. 10(1). R22–R22. 257 indexed citations
18.
He, Shui, Sati Mazumdar, & Vincent C. Arena. (2005). A comparative study of the use of GAM and GLM in air pollution research. Environmetrics. 17(1). 81–93. 42 indexed citations
19.
He, Shui. (2004). GENERALIZED ADDITIVE MODELS FOR DATA WITH CONCURVITY: STATISTICAL ISSUES AND A NOVEL MODEL FITTING APPROACH. D-Scholarship@Pitt (University of Pittsburgh). 6(18). 717–26. 4 indexed citations
20.
Krichevsky, Alexander, et al.. (2003). Initial plasma levels of lipopolysaccharide binding protein are associated with severe sepsis in patients with community-acquired pneumonia. Critical Care. 7(Suppl 2). P032–P032. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruno Royer Breakdown of academic impact, for papers by Piera Viero Breakdown of academic impact, for papers by P. W. Wijermans Breakdown of academic impact, for papers by Eirini Katodritou Breakdown of academic impact, for papers by Megan O. Nakashima Breakdown of academic impact, for papers by Paolo G. Gobbi Breakdown of academic impact, for papers by Achille Ambrosetti Breakdown of academic impact, for papers by David Lawrence Breakdown of academic impact, for papers by Lars Møller Pedersen Breakdown of academic impact, for papers by Canellos Gp
Rankless by CCL
2026